Stockreport

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK [Yahoo! Finance]

CureVac N.V. - Ordinary Shares  (CVAC) 
PDF Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone Avian influenza is latest program [Read more]